www.fdanews.com/articles/84890-biosante-pharmaceuticals-signs-option-and-license-for-its-cap-technology-for-use-in-aesthetic-medicine
BIOSANTE PHARMACEUTICALS SIGNS OPTION AND LICENSE FOR ITS CAP TECHNOLOGY FOR USE IN AESTHETIC MEDICINE
February 27, 2006
BioSante Pharmaceuticals, Inc. today announced that it has signed an exclusive
option and license agreement with Medical Aesthetics Technology Corporation
("MATC") for the use of BioSante's calcium phosphate nanotechnology
(CaP) in the field of aesthetic medicine. Under the terms of the option and
license agreement, MATC will use BioSante's CaP technology to develop products
for commercialization in the field of aesthetic medicine, specifically, the
improvement and/or maintenance of the external appearance of the head, face,
neck and body.
Business
Wire